Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 2 Neuroendocrine Tumors 1 Inflammatory Breast Neoplasms 1

Interventions

Everolimus 17 lutetium Lu 177 dotatate 7 Octreotide 7 pasireotide 6 lanreotide 6 gallium Ga 68 dotatate 5 Temozolomide 5 Sunitinib 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 pembrolizumab 4 Sorafenib 4 Data Collection 4 Carboplatin 4 3-Iodobenzylguanidine 4 Positron-Emission Tomography 3 Nivolumab 3 Etoposide 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pazopanib 2 lenvatinib 2 fosbretabulin 2 fluorodopa F 18 2 cabozantinib 2 avelumab 2 arginyllysine 2 Single Photon Emission Computed Tomography Computed Tomography 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroendocrine Tumors × 89Zr-bevacizumab × Clear all

NCT01338090 2012-04-03

NETPET

University Medical Center Groningen

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡